Also categorized in Clinical Research:
A Phase I Study of Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
x hide permanently

Dinutuximab for maintenance therapy in pediatric neuroblastoma.

ncbi.nlm.nih.gov

Dinutuximab for maintenance therapy in pediatric neuroblastoma.

Am J Health Syst Pharm. 2017 Apr 15;74(8):563-567

Authors: McGinty L, Kolesar J

Abstract PURPOSE: The pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.

Mentions: Treatment